STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson’s disease
Fasano, A. et al. Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133, 2664–2676 (2010).
Bove, F. et al. Long-term outcomes (15 years) after subthalamic nucleus deep brain stimulation in patients with parkinson’s disease. Neurology 97, e254–e262 (2021).
Dafsari, H. S. et al. Beneficial effects of bilateral subthalamic stimulation on non-motor symptoms in Parkinson’s disease. Brain Stimul. 9, 78–85 (2016).
Bellini, G., Best, L. A., Brechany, U., Mills, R. & Pavese, N. Clinical impact of deep brain stimulation on the autonomic system in patients with Parkinson’s disease. Mov. Disord. Clin. Practice 7, 373–382 (2020).
Fasano, A., Visanji, N. P., Liu, L. W., Lang, A. E. & Pfeiffer, R. F. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 14, 625–639 (2015).
Rana, A. Q. et al. Impact of cognitive dysfunction on drooling in Parkinson’s disease. Eur. Neurol. 70, 42–45 (2013).
Srivanitchapoom, P., Pandey, S. & Hallett, M. Drooling in Parkinson’s disease: a review. Parkinsonism Relat. Disord. 20, 1109–1118 (2014).
Rodrigues, B., Nobrega, A. C., Sampaio, M., Argolo, N. & Melo, A. Silent saliva aspiration in Parkinson’s disease. Mov. Disord. 26, 138–141 (2011).
Xie, T. et al. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J. Neurol. Neurosurg. Psychiatry 89, 989–994 (2018).
Chang, M. C., Park, J. S., Lee, B. J. & Park, D. The effect of deep brain stimulation on swallowing function in Parkinson’s disease: a narrative review. Dysphagia 36, 786–799 (2021).
Thobois, S. et al. Subthalamic nucleus stimulation in Parkinson’s disease: clinical evaluation of 18 patients. J. Neurol. 249, 529–534 (2002).
Rizzone, M. G. et al. Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat. Disord. 20, 376–381 (2014).
Defer, G. L., Widner, H., Marie, R. M., Remy, P. & Levivier, M. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov. Disord. 14, 572–584 (1999).
Perez-Lloret, S. et al. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort. Eur. J. Neurol. 19, 28–37 (2012).
Martinez-Martin, P. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. J. Neurol. 259, 1639–1647 (2012).
Fereshtehnejad, S. M., Skogar, O. & Lokk, J. Evolution of orofacial symptoms and disease progression in idiopathic Parkinson’s disease: longitudinal data from the Jonkoping Parkinson registry. Parkinsons Dis. 2017, 7802819 (2017).
Savica, R. et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 70, 1396–1402 (2013).
Nobrega, A. C. et al. Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease? Parkinsonism Relat. Disord. 14, 243–245 (2008).
van Wamelen, D. J. et al. Drooling in Parkinson’s disease: prevalence and progression from the non-motor international longitudinal study. Dysphagia 35, 955–961 (2020).
Hacker, M. L. et al. Deep brain stimulation in early-stage Parkinson disease: five-year outcomes. Neurology 95, e393–e401 (2020).
Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181–184 (1992).
Fasano, A. et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease and small intestinal bacterial overgrowth. Clin. Neuropharmacol. 37, 91–95 (2014).
Piano, C. et al. An Italian neurology outpatient clinic facing SARS-CoV-2 pandemic: data from 2,167 patients. Front Neurol. 11, 564 (2020).
Fahn, S., Elton, R. & and Members of the UPDRS Development Committee. in Recent Developments in Parkinson’s Disease Vol. 2 (eds. Fahn, S., Marsden, C.D., Calne, D.B. & Goldstein, M.) 153–163 (Macmillan Healthcare Information, 1987).
Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427–442 (1967).
Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653 (2010).